Central Asian Research Index

Journal of Clinical Medicine of Kazakhstan, 2026, т. 23, № 4, с. 14-24

Effectiveness and Safety of Lanadelumab in the Treatment of Patients with Hereditary Angioedema in Routine Clinical Practice in the Russian Federation.

Tatiana Nekrasova, Liubov Aleshina, Elena Bobrikova, Ekaterina Viktorova, Elena Volkova, Elena Gracheva, Darya Demina, Olga Ivanitskaya, Marina Karakina, Natalia Kuzmenko, Irina Lyulyu, Irina Manto, Nikolay Nazarov, Dar’ya Fomina, Anna Shcherbina, Tatiana Latysheva, Elena Latysheva

Department of Immunopathology, National Research Center – Institute of Immunology Federal Medical-Biological Agency, Moscow, Russia
Department of Clinical Immunology and Allergology, Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia
Moscow City Research and Practical Center of Allergy and Immunology, City Clinical Hospital 52, Moscow Healthcare Department, Moscow, Russia
Department of Clinical Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Department of Allergology and Immunology, Smolensk Clinical Hospital №1, Regional Center of Allergology and Immunology, Smolensk, Russian Federation
Counselling outpatient clinic, Vologda regional clinical hospital, Vologda, Russian Federation
Department of Allergology, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
Department of Clinical Medicine, Murmansk Arctic University, Murmansk, Russian Federation
Consultative and diagnostic department, Sverdlovsk Regional Clinical Hospital, Ekaterinburg, Russian Federation
Department of Pulmonology, Republican Hospital named after V.A. Baranov, Petrozavodsk, Republic of Karelia, Russian Federation
Clinical and diagnostic department, DOCMED clinic
Moscow City Research and Practical Center of Allergy and Immunology, City Clinical Hospital 52, Moscow Healthcare Department, Moscow, Russian Federation; Department of Clinical Immunology and Allergy, The First Sechenov State Medical University, Moscow, Russia

Аннотация · Abstract

<b>Background:</b>&nbsp;Hereditary angioedema (HAE) caused by C1 inhibitor deficiency is a rare condition marked by recurrent swelling of the skin and mucous membranes. This study evaluated the effectiveness and safety of lanadelumab in routine clinical practice in Russia (IISR-2021-200085).<br /> <b>Methods:</b>&nbsp;A prospective cohort of 30 individuals with HAE was observed. Most patients were women (87%), with a mean age of 34 years; Seventeen percent of participants were adolescents. Prior to initiating lanadelumab, 16 patients (53%) had been receiving long-term prophylaxis, which was discontinued once lanadelumab was started. Treatment outcomes were assessed by comparing attack frequency, medication use for acute events, disease control scores, and quality of life before and after lanadelumab therapy.<br /> <b>Results:</b>&nbsp;Before treatment, patients reported an average of 8.6 attacks per month. After 6 months of lanadelumab treatment, the mean attack frequency was reduced to 0.5 per month (p &lt; 0.001). Use of acute therapies decreased from 4.73 to 0.43 doses per month (p &lt; 0.001). Disease control improved substantially, and quality-of-life scores improved from 58.2 to 25.3 points (p &lt; 0.001). No significant lanadelumab-related adverse events were observed.<br /> <b>Conclusion:</b>&nbsp;In routine clinical practice, lanadelumab proved highly effective in reducing attack rates, enhancing disease control, and improving quality of life in patients with hereditary angioedema. The therapy was well tolerated, with no serious safety concerns identified. These findings reinforce lanadelumab as a reliable long-term prophylactic option for hereditary angioedema management.

Сведения · Details